Results to your Biomarker

Biomarker
Exposure to
Matrix
Analytical Technique
Nicotine (Nic)
Nicotine
Urine, Plasma, Serum, Saliva, PBS, ETS, e-liquids, aerosol
LC-MS/MS, GC-MS

Matching services

tobacco

Tobacco Harm Reduction

With over four decades of experience, ABF is a globally leading expert in bioanalysis for biomarkers of exposure related to tobacco and new emerging nicotine products, trusted by clients worldwide. We have analyzed biological samples for hundreds of (non-)clinical studies, applying the largest set of fully validated bioanalytical methods in the field of tobacco harm reduction. We continuously expand our portfolio by developing and validating bioanalytical methods for new biomarkers of exposure and biomarkers of potential harm, staying at the forefront of scientific advancements. At ABF, we are committed to help our clients responsibly launch new nicotine products in the marketplace. Choose ABF for reliable and cutting-edge bioanalysis services in the field of tobacco harm reduction.

Scientific Contribution

Conference contribution
October 2013

Assessing the exposure to ‘smoke’ from electronic cigarettes by biomarkers

CORESTA SSPT 2013, Seville, Spain
publication
March 2022

Assessment of nicotine delivery and uptake in users of various tobacco / nicotine products

Current Research in Toxicology, Volume 3, 100067
publication
March 2019

Biomarkers of Exposure Specific to E-vapor Products Based on Stable-Isotope Labeled Ingredients

Nicotine & Tobacco Research, Volume 21, doi: 10.1093/ntr/nty204
Conference contribution
February 2018

Biomarkers of exposure specific to e-vapor products based on stable-isotope labeled ingredients

SRNT 2018, Baltimore, USA
Conference contribution
October 2017

Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients – methods

CORESTA SSPT 2017, Kitzbühel, Austria
Conference contribution
October 2017

Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients–results

CORESTA SSPT 2017, Kitzbühel, Austria
Conference contribution
October 2017

Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients–study design

CORESTA SSPT 2017, Kitzbühel, Austria
publication
May 2018

Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine

Cancer Epidemiology, Biomarkers & Prevention, Volume 27, doi: 10.1158/1055-9965
publication
March 2014

Saliva as a matrix for human biomonitoring in occupational and environmental medicine

International Archives of Occupational and Environmental Health, volume 88, doi: 10.1007/s00420-014-0938-5
publication
January 2014

Simple, fast and sensitive LC-MS/MS analysis for the simultaneous quantification of nicotine and 10 of its major metabolites

Journal of Chromatography B, Volumes 951–952, doi: 10.1016/j.jchromb.2014.01.025
Conference contribution
October 2016

Ultra-sensitive method for the determination of nicotine in PK studies with next generation products

CORESTA Congress 2016, Berlin, Germany